Alnylam Pharmaceuticals has highlighted significant pipeline progress and platform innovation at their R&D Day. Despite being among the oversold BioTech stocks, it remains a promising buy. Diverse financial institutions have fluctuated their shares in the company, with some increasing their position, such as Proficio Capital Partners, others decreasing such as Los Angeles Capital and some maintaining an 'Outperform' rating like the Royal Bank of Canada and William Blair. Alnylam has made significant progress in clinical trials, reducing mortality by 36% and preparing 9 new drug candidates by 2025. They have also submitted a regulatory application to the European Medicines Agency and the US Food and Drug Administration for the treatment of ATTR Amyloidosis with Cardiomyopathy. Their Q4 earnings and revenue estimates have surpassed expectations, but their yearly EPS missed the mark. The stock price has seen some ups and downs, but their progressive pipeline and pending approvals have led to a cautious hold on the stock. Organic growth and robust pipeline may reinforce their securities, paving the way to reach their ambitious revenue target for 2025 of $2.25 billion.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 01 Mar 2025 11:40:20 GMT - Rating 7 - Innovation 9 - Information 8 - Rumor -2
